Claims for Patent: 10,203,343

Summary for Patent: 10,203,343

Title:	Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (EGF)
Abstract:	The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (EGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor.
Inventor(s):	Heidecke; Harald (Berlin, DE), Schulze-Forster; Kai (Berlin, DE)
Assignee:	CELLTREND GMBH (Luckenwalde, DE)
Application Number:	15/116,476
Patent Claims:	1. A method for diagnosis and treatment of ovarian cancer, comprising the steps of; administering, to a subject diagnosed with ovarian cancer, a drug that is an inhibitor of EGF receptor activity, a monoclonal antibody that binds to an EGF receptor, or panitumumab, wherein the ovarian cancer is diagnosed by: (a) measuring the level of antibodies against epidermal growth factor (EGF) (anti-EGF antibodies) in a serum sample from a subject to be diagnosed, wherein the anti-EGF antibodies bind to recombinant mature EGF of SEQ ID NO:2; and (b) comparing the measured level of anti-EGF antibodies in the sample to a control level of anti-EGF antibodies derived from subjects without cancer; wherein a decreased level of anti-EGF antibodies in the sample from the subject to be diagnosed as compared to the control level is indicative of ovarian cancer in the subject. 2. The method of claim 1, wherein a level of anti-EGF antibodies below 47 units/ml is indicative of ovarian cancer. 3. The method of claim 1, wherein the anti-EGF antibody is detected in an immunoassay. 4. The method of claim 3, wherein the immunoassay is selected from the group consisting of immunoprecipitation, enzyme immunoassay (EIA), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassay, a chemiluminescent assay, an agglutination assay, nephelometric assay, turbidimetric assay, a Western Blot, a competitive immunoassay, a noncompetitive immunoassay, a homogeneous immunoassay a heterogeneous immunoassay, a bioassay and a reporter assay. 5. The method of claim 1, wherein measuring the level of anti-EGF antibodies comprises the steps of: (a) contacting the sample with epidermal growth factor (EGF) or an antigenic peptide fragment thereof under conditions allowing for the formation of a complex between anti-EGF antibodies with EGF or a peptide fragment thereof, wherein the anti-EGF antibodies bind to recombinant mature EGF of SEQ ID NO:2; and (b) detecting the complex. 6. The method of claim 5, wherein the EGF or the peptide fragment thereof is immobilized on a surface. 7. The method of claim 5, wherein the complex is detected using a secondary antibody against the Fc portion of the anti-EGF antibody. 8. The method of claim 7, wherein the anti-EGF antibody is an IgG-antibody and the secondary antibody is an anti-IgG antibody. 9. The method of claim 8, wherein the secondary antibody is labeled with a detectable marker.

Details for Patent 10,203,343

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2034-02-04